Databridgemarketresearch.com Present “
Cancer Gene Therapy Market – Industry Trends and Forecast to 2028” new report to its research database. Due to the potential of SWOT analysis and Porter’s Five Forces analysis in generating market research report, they are preferred by the businesses and hence also used while making this report. To structure such a world-class report, the combination of best industry insight, practical solutions, talent solutions and latest technology have been used. As today’s businesses demand the market research analysis to a great extent before taking any verdict about the products, choosing such market research report is essential for the businesses. DBMR team is committed to present the market research report that is promising and the way in which it is foreseen.
Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo.
CounterPath Corporation (NASDAQ: CPAH)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
CounterPath Corporation (NASDAQ: CPAH) in connection with the proposed acquisition of the company by Alianza, Inc. Under the terms of the agreement, CPAH shareholders will receive only $3.49 in cash for each share of CPAH common stock they own. If you own CPAH shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/cpah/
Cardtronics plc (NASDAQ: CATM)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
/PRNewswire/ If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.